Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures-Reference-Cited by-同舟云学术

Open‐label study to investigate the safety and efficacy of adjunctive perampanel in pediatric patients (4 to <12 years) with inadequately controlled focal seizures or generalized tonic‐clonic seizures

Published:2020-01 Issue:1 Volume:61 Page:125-137
ISSN:0013-9580
Container-title:Epilepsia
language:en
Short-container-title:Epilepsia

Author:

Fogarasi Andras¹,Flamini Robert²,Milh Mathieu³,Phillips Steven⁴,Yoshitomi Shinsaku⁵^ORCID,Patten Anna⁶,Takase Takao⁷,Laurenza Antonio⁸,Ngo Leock Y.⁹

Affiliation:

1. Epilepsy Center Bethesda Children’s Hospital Budapest Hungary

2. Pediatric and Adolescent Neurodevelopmental Associates Atlanta GA USA

3. Pediatric Neurology Unit La Timone Enfants Hospital Marseille France

4. Mary Bridge Children’s Neurology Clinic Tacoma WA USA

5. NHO Shizuoka Institute of Epilepsy and Neurological Disorders Shizuoka Japan

6. Eisai Ltd. Hatfield, Hertfordshire UK

7. Eisai Co., Ltd. Tokyo Japan

8. Formerly: Eisai Inc. Woodcliff Lake NJ USA

9. Eisai Inc. Woodcliff Lake NJ USA

Funder

Eisai

Publisher

Wiley

Subject

Clinical Neurology,Neurology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/epi.16413

Reference24 articles.

1. The AMPA receptor as a therapeutic target in epilepsy: preclinical and clinical evidence

2. The impact of perampanel and targeting AMPA transmission on anti-seizure drug discovery

3. European Medicines Agency (EMA).Fycompa®Annex I: summary of product characteristics. Available at:https://www.ema.europa.eu/en/documents/product-information/fycompa-epar-product-information_en.pdf. Accessed December 16 2019.

4. Food and Drug Administration (FDA).Fycompa®Prescribing Information May 2019. Available at:https://www.fycompa.com/-/media/Files/Fycompa/Fycompa_Prescribing_Information.pdf. Accessed December 16 2019.

5. Randomized phase III study 306: Adjunctive perampanel for refractory partial-onset seizures

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Long-term efficacy, safety, and tolerability, including behavior and executive functioning, during adjunctive lacosamide treatment in pediatric patients with uncontrolled epilepsy;Epilepsy & Behavior;2024-10

2. Efficacy and safety of adjunctive perampanel treatment in pediatric patients with epilepsy aged 4–12 years: a real-world study;Journal of Neurology;2024-05-08

3. Efficacy and safety of perampanel as the first add-on therapy for children with epilepsy: A real-world multicenter prospective observational study;Seizure: European Journal of Epilepsy;2024-04

4. Role of Perampanel in the Management of Pediatric Epilepsies in Asia: Expert Opinion;Pediatric Neurology;2024-02

5. Pathophysiology to Risk Factor and Therapeutics to Treatment Strategies on Epilepsy;Brain Sciences;2024-01-10